Forty-two patients in the acute phase of onyalai were admitted to hospital and randomly divided into three groups of 14 to receive prednisolone 3 mg/kg/d for 1 week, intravenous gammaglobulin 100 mg/kg on 2 successive days, or ascorbic acid 1000 mg 3 times a day for 1 week. The groups were comparable with regard to sex and age distribution, initial platelet counts and initial haemoglobin values. No statistical difference was observed between the three treatment groups with regard to changes in the platelet counts during the period of observation. One patient died from haemorrhagic shock. The low mortality rate in this series suggests that admission to hospital and early correction of blood loss are important factors in reducing the mortality rate associated with onyalai.

Download full-text PDF

Source

Publication Analysis

Top Keywords

intravenous gammaglobulin
8
ascorbic acid
8
platelet counts
8
mortality rate
8
treatment onyalai
4
onyalai prednisolone
4
prednisolone intravenous
4
gammaglobulin ascorbic
4
acid prospective
4
prospective clinical
4

Similar Publications

Protein aggregation, a major concern in biopharmaceutical quality control, can be accelerated by various stresses during clinical handling. This study investigated potential aggregation risk factors during dilution process with syringe handling for intravenous administration. Using γ-globulin and IgG solutions as surrogate models of antibody therapeutics, we examined the effects of high sliding speeds and piston operations of the syringe on protein aggregation during saline dilution.

View Article and Find Full Text PDF

There is no established treatment for late or chronic antibody-mediated rejection of a kidney graft. Rituximab-based treatment is not effective, since long-lived high-affinity plasma cells do not express CD20 and do not depend on previous maturation steps to generate donor-specific antibodies. Conversely, daratumumab, an anti-CD38 monoclonal antibody, directly targets plasma cells, with proven efficacy in multiple myeloma.

View Article and Find Full Text PDF
Article Synopsis
  • The study assessed the effectiveness of a modified regimen (mRAISE) using corticosteroids as an adjunctive therapy along with IVIG and aspirin for high-risk Kawasaki Disease (KD) patients in North America.
  • A total of 221 patients were reviewed from 2010 to 2023, with 83 receiving the mRAISE treatment and 138 not.
  • Results showed no significant differences in coronary artery outcomes between the two groups, but mRAISE patients were less likely to require multiple doses of IVIG compared to those who did not receive this regimen.
View Article and Find Full Text PDF

Objective: To evaluate the efficacy of different doses of gammaglobulin combined with aspirin in treating pediatric Kawasaki disease and its impact on C-reactive protein (CRP) and white blood cell (WBC) levels.

Methods: A prospective study was conducted with 150 children (3groups) diagnosed with Kawasaki disease. Group A received a higher dose of intravenous gammaglobulin (2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!